Atom Therapeutics
June 22, 2026
Theater 1
Type: Company Presentation
Focus Area:
Inflammation
Atom Therapeutics is privately held clinical stage Chinese biotech company founded in 2012. Atom is developing best-in-class oral small molecule drugs for treatment of inflammatory, metabolic and cardiovascular disease. Lingdolinurad (ABP-671), Atom's lead program for treatment of chronic gout is expected to be more effective and better tolerated than current gout treatments making it more suitable for chronic gout treatment. Lingdolinurad is expected to enter into global phase 3 studies in the second half of 2026.
A second compound, ABP-745 is in multi-country phase 2 stage for multiple indications, including treatment of acute gout flares and atherosclerotic cardiovascular disease. Other earlier stage pipeline products include ABP-6616 for atrial fibrillation and ABP-6016 for MASH, both in preclinical stage with IND targeted in 2027.
Company HQ City:
501 Fucheng Road, Qiantang District, Hangzhou City
Company HQ State:
Zhejiang Province,
Company HQ Country:
China
Year Founded:
2012
Lead Product in Development:
Lingdolinurad (ABP-671) new URAT1 inhibitor for treatment of chronic gout
CEO
William Dongfang Shi, Ph.D., Founder, Chairman and CEO
Development Phase of Lead Product
Phase III
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
ABP-745 data readout: Oct. 2026
Lingolinurad initiation of global phase 3 studies: Dec. 2026
What is your next catalyst (value inflection) update?
1) Initiation of phase 3 pivotal studies for lingdolinurad for chronic gout
2) Data readout from ABP-745 phase 2 study for treatment of acute gout flares
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}